Relevant bibliographies by topics / HR+/HER2− metastatic breast cancer

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'HR+/HER2− metastatic breast cancer'

Author: Grafiati
Published: 2 June 2025
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'HR+/HER2− metastatic breast cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "HR+/HER2− metastatic breast cancer"

1

Khan, Noman Ahmed Jang, Mahmoud Abdallah, and Maria Tria Tirona. "Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case." Journal of Investigative Medicine High Impact Case Reports 9 (January 2021): 232470962110221. http://dx.doi.org/10.1177/23247096211022186.

Full text
Abstract:
Breast cancer is the most common cancer diagnosed in women in North America. Hormone receptor positive (HR+) and HER2 negative (HER2−) breast cancers account for at least 60% to 70% of all breast cancer cases. They usually metastasize to lymph nodes, bones, liver, lungs, and brain. Urinary bladder is a very unusual site for metastatic HR+/HER2− breast cancer and occurs in only 2% of all metastatic disease. In this article, we present a case of a 63-year-old female with locally advanced breast cancer who underwent mastectomy, adjuvant chemotherapy, radiation, and hormonal therapy. She was in re
APA, Harvard, Vancouver, ISO, and other styles
2

Hrizat, A. S., and E. Brachtel. "Proliferation Index in “HER2 Low” Metastatic Breast Cancer." American Journal of Clinical Pathology 160, Supplement_1 (2023): S13—S14. http://dx.doi.org/10.1093/ajcp/aqad150.030.

Full text
Abstract:
Abstract Introduction/Objective There is considerable genetic heterogeneity between primary and metastatic breast cancer. The new classification of the "HER2-low" category includes tumors characterized by a low level of HER2 expression (immunohistochemistry (IHC) score 1+ or 2+ without in situ hybridization (ISH) amplification), in addition to the known HER2 negative (HER2-0) and HER2+ (amplified) cases. The Ki67 proliferation index (PI) can predict breast cancer prognosis. Proliferation changes in metastatic breast cancer and in different HER2 categories are not well delineated in clinical co
APA, Harvard, Vancouver, ISO, and other styles
3

Zhu, Anjie, and Hui-Ping Li. "Abstract PO2-05-13: HER2 status presented an unstable switching from primary to recurrent breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO2–05–13—PO2–05–13. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-05-13.

Full text
Abstract:
Abstract Background: Breast cancer patients with HER2-2+ expression had heterogeneous characteristic. Treatment decision is of great importance after progression. Objective: We explored patients with HER2-2+ in matched primary or recurrent/metastatic tumor samples from January 2010 to June 2022 in our institute were included to evaluate the evolution from or to HER2-2+ expression. Meanwhile, with an emerging of novel entity as HER2-low expression breast cancer, we included this category when analysis as well. Results: In the cohort of a total of 159 breast cancer patients with HER2-2+ expressi
APA, Harvard, Vancouver, ISO, and other styles
4

Han, Yiqun, Yun Wu, Hangcheng Xu, Jiayu Wang, and Binghe Xu. "The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study." International Journal of Clinical Oncology 27, no. 4 (2022): 707–16. http://dx.doi.org/10.1007/s10147-022-02115-x.

Full text
Abstract:
Abstract Background To investigate the impact of hormone receptor (HR) on the clinicopathological characteristics and prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Methods Using the Surveillance, Epidemiology, and End Results database, we enrolled patients diagnosed with HER2-positive breast cancer between 2010 and 2016, which were successively assessed for eligibility and categorized into HR + /HER2 + and HR-/HER2 + subgroups. Clinicopathological characteristics were undergone comparative analyses with the baseline distinctions calibrated by propensity s
APA, Harvard, Vancouver, ISO, and other styles
5

Zhang, Shaohua, Tao Wang, Li Bian, Guohui Han, Xiangdong Bai, and Zefei Jiang. "Abstract P5-10-21: Efficacy and safety of utidelone plus bevacizumab in the treatment of patients with Her2- metastatic breast cancer study." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–10–21—P5–10–21. https://doi.org/10.1158/1557-3265.sabcs24-p5-10-21.

Full text
Abstract:
Abstract Background: Despite the rapid development of targeted therapy and immunotherapy for breast cancer in recent years, Chemotherapy remains an important treatment for metastatic breast cancer (MBC), and currently there is no standard chemotherapy regimen for MBC patients previously treated with taxanes. Utidelone is a new microtubule inhibitor drug developed in China, which has demonstrated excellent efficacy for metastatic breast cancer. Historical studies have shown that chemotherapy combined with angiogenic inhibitors can improve PFS in advanced breast cancer patients compared with che
APA, Harvard, Vancouver, ISO, and other styles
6

Lv, Huimin, Min Yan, Mengwei Zhang, et al. "Abstract PO1-06-05: Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO1–06–05—PO1–06–05. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-06-05.

Full text
Abstract:
Abstract Background: It remains uncertain as to whether low levels of HER2 positivity have any prognostic implications in breast cancer patients, whether HER2 levels can be inconsistent between primary tumors and metastatic lesions in individuals with advanced HER2-negative breast cancer, and how such inconsistencies may impact patient prognosis. Methods: A retrospective analysis of advanced breast cancer patients admitted to our hospital from from January 1st, 2010 to January 1st, 2019 was performed, with all patients that underwent at least one metastatic lesion biopsy being screened. The ho
APA, Harvard, Vancouver, ISO, and other styles
7

Niikura, Naoki, Jun Liu, Naoki Hayashi, et al. "Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors." Journal of Clinical Oncology 30, no. 6 (2012): 593–99. http://dx.doi.org/10.1200/jco.2010.33.8889.

Full text
Abstract:
Purpose We evaluated whether patients with human epidermal growth factor receptor 2 (HER2) –positive primary breast tumors had metastatic tumors that were HER2 positive (concordant) or HER2 negative (discordant). We then evaluated whether treatment with trastuzumab or chemotherapy before biopsy of the metastasis had any effect on the rate of HER2 discordance. We also compared the overall survival durations of patients with HER2-concordant and -discordant tumors. Patients and Methods We retrospectively identified all patients who initially had been diagnosed with HER2-positive (immunohistochemi
APA, Harvard, Vancouver, ISO, and other styles
8

Shin, Junghoon, Ji-Yeon Kim, Jung Min Oh, et al. "Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer." Cancers 15, no. 19 (2023): 4720. http://dx.doi.org/10.3390/cancers15194720.

Full text
Abstract:
Background: Elucidating the clinical features of metastatic breast cancer (MBC) patients with an exceptionally favorable prognosis may offer insights to improve the survival of more typical patients. Methods: We collected comprehensive real-world data on clinicopathologic characteristics, treatments, and outcomes of 110 consecutive MBC patients who survived for over ten years from the clinical data warehouse of Samsung Medical Center. Results: The cohort included 54 hormone receptor (HR)-positive/HER2-negative (HR+/HER2−), 21 HR+/HER2+, 16 HR−/HER2+, and 14 triple-negative breast cancer (TNBC)
APA, Harvard, Vancouver, ISO, and other styles
9

Hasan, Shaakir, Zachary Neubauer, Robert H. Press, et al. "Prognostic implications of HER2Neu-low in metastatic breast cancer." Journal of Clinical Oncology 40, no. 16_suppl (2022): 1044. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1044.

Full text
Abstract:
1044 Background: HER2-Low (or HER2-equivocal, FISH negative) breast cancer has historically been treated as HER2-negative; however, recent evidence suggests that there may be prognostic and/or predictive differences between the two. We explore demographic characteristics and clinical outcomes of HER2-negative and HER2-low metastatic breast cancer (MBC) patients using real world data. Methods: We queried the National Cancer Database to identify MBC patients that were HER2 0, HER2 1+, or HER2 2+ per immunohistochemical staining, with the latter two defined as HER2-low and the former HER2-negativ
APA, Harvard, Vancouver, ISO, and other styles
10

Lucas, Tylan, Joshua Chan, and Neha Chopra. "Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients." Oncology & Haematology 19, no. 1 (2023): 1. http://dx.doi.org/10.17925/ohr.2023.19.1.1.

Full text
Abstract:
Metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer survival outcomes have improved significantly; however, once endocrine resistance develops, response rates to systemic treatments are limited. Within the developing field of antibody–drug conjugates, the TROPiCS-02 study showed a significant improvement in progression-free survival with sacituzumab govitecan compared with physician’s choice of chemotherapy in patients with endocrine-resistant, metastatic, HR+/HER2- breast cancer. Additionally, overall survival similarly improved (
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "HR+/HER2− metastatic breast cancer"

1

Hall, Charles. "Ex vivo reprogramming of tumor-reactive immune cells from FVBN202 mice bearing lung metastatic mammary carcinoma: an immunotherapeutic opportunity revealed against recurrence." VCU Scholars Compass, 2013. http://scholarscompass.vcu.edu/etd/3176.

Full text
Abstract:
Metastatic breast cancer treatment has seen few advances in recent years, yet treatment resistance continues to rise, causing disease recurrence. A pilot study was performed to determine the efficacy of ex vivo expansion and reprogramming of tumor-reactive immune cells from experimental metastatic tumor-sensitized mice. Also, phenotypic changes in tumors due to metastasis or tumor microenvironment influences were characterized. Metastatic neu+ mouse mammary carcinoma (mMMC) and its distant relapsing neu-antigen-negative variant (mANV) were investigated in FVBN202 mice. Tumor-reactive central m
APA, Harvard, Vancouver, ISO, and other styles
2

Monteiro, Inês de Paula Costa. "Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies." Master's thesis, 2016. https://repositorio-aberto.up.pt/handle/10216/83769.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Monteiro, Inês de Paula Costa. "Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies." Dissertação, 2016. https://repositorio-aberto.up.pt/handle/10216/83769.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Yeh, Ying-Chih, and 葉盈池. "Effectiveness and Cost-Effectiveness of Trastuzumab Emtansine in Women with HER2-Positive Locally Advanced or Metastatic Breast Cancer: A Systematic Review and Meta-Analysis." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/c8et72.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Šlegerová, Lenka. "Hodnocení zdravotní technologie (HTA): léčba karcinomu prsu, případová studie ČR." Master's thesis, 2019. http://www.nusl.cz/ntk/nusl-392652.

Full text
Abstract:
Health technology assessment: case study on breast carcinoma treatment in the Czech Republic Bc. Lenka Šlegerová January 4, 2019 Abstract This thesis proposes an original method for assessing total costs of med- ical treatment. It defines the semi-Markov model with four states that are associated with specific costs of the treatment, and not with patients' health statuses. This method is applied to individuals' treatment data drawn from the Czech clinical practice in the treatment of the metastatic HER2+ breast cancer. The aim is to assess the cost-effectiveness of adding medication per- tuzum
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "HR+/HER2− metastatic breast cancer"

1

Oehlrich, Marcus. Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene: A systematic review. dissertation.de, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Preusser, Matthias, Gabriele Schackert, and Brigitta G. Baumert. Metastatic brain tumours. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0019.

Full text
Abstract:
Brain metastasis is a common clinical challenge in cancer patients, particularly those with lung cancer, breast cancer, and melanoma. The prognosis is poor, with median overall survival times measured in months for most patient populations. Established treatments include neurosurgical resection, radiotherapy (including stereotactic radiosurgery and stereotactic radiotherapy, whole-brain radiotherapy, and new radiation techniques), and supportive care measures. Recently, more and more targeted therapies such as EGFR inhibitors, HER2 antagonists, BRAF inhibitors, ALK inhibitors, and immune check
APA, Harvard, Vancouver, ISO, and other styles
3

Cassidy, Jim, Donald Bissett, Roy A. J. Spence OBE, Miranda Payne, Gareth Morris-Stiff, and Amen Sibtain. Colorectal cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199689842.003.0015_update_001.

Full text
Abstract:
Breast cancer reviews the epidemiology and aetiology of this malignancy, with particular attention to the genetics underlying familial breast cancer, its pathology along with its receptors, oestrogen receptor (ER), the growth factor receptor HER2, and epidermal growth factor receptor (EGFR), and the bearing these have on treatment and prognosis. The benefits of breast cancer screening in the population and families at higher risk are discussed. Presenting symptoms and signs are followed by investigation including examination, bilateral mammography, and core biopsy of suspicious lesions. Manage
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "HR+/HER2− metastatic breast cancer"

1

Kwon, Youngmi, Yunju Kim, Bo Hwa Choi, et al. "HR(−) HER2(+) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, Eun Sook, Chan Wha Lee, Youngmi Kwon, Jeayeon Woo, and Yunju Kim. "HR(−) HER2(−) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kim, Yunju, Bo Hwa Choi, Eun-Gyeong Lee, Ji Young You, and Youngmi Kwon. "HR(+) HER2(−) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Park, Soojin, Ran Song, Yunju Kim, et al. "HR(+) HER2(+) Breast Cancer." In A Practical Guide to Breast Cancer Treatment. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-19-9044-1_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Imamović, Elma, Anisa Veledar, Zerina Kalić, Adna Softić, Emina Mrđanović, and Merima Smajlhodžić-Deljo. "Impact of PET and PET/CT Radiotracer for Evaluating Efficacy of CDK4/6 Inhibitor Therapy in HR-Positive HER2-Negative Metastatic Breast Cancer." In IFMBE Proceedings. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-49062-0_38.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bayraktar, Soley, and Adnan Aydiner. "Systemic Treatment of HER2-Negative Metastatic Breast Cancer." In Breast Cancer. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96947-3_22.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Aydiner, Adnan. "Systemic Treatment of HER2-Overexpressing Metastatic Breast Cancer." In Breast Cancer. Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-96947-3_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Aydiner, Adnan. "Treatment of HER2-Overexpressing Metastatic Breast Cancer." In Breast Disease. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-26012-9_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Aydiner, Adnan. "Treatment of HER2-Overexpressing Metastatic Breast Cancer." In Breast Disease. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_32.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bayraktar, Soley, and Adnan Aydiner. "Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy." In Breast Disease. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16792-9_31.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "HR+/HER2− metastatic breast cancer"

1

Freitas, Paola Ferreira de, Renata Borges de Aquino, Andre Mattar, Jorge Yoshinori Shida, and Luiz Henrique Gebrim. "CASE REPORT: PATHOLOGICAL COMPLETE RESPONSE IN BREAST IN A PATIENT WITH METASTATIC BREAST CANCER TREATED WITH ANASTROZOLE." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2088.

Full text
Abstract:
Background: De novo metastatic breast cancer is seldomly encountered in patients visiting doctor’s clinics for the first time. This article reports a case of cervical/submandibular metastatic breast cancer treated with neoadjuvant endocrine therapy (NET) with anastrozole (ANA). Case description: We herein report on a patient affected by HR+, HER2−, and metastatic breast cancer treated with NET that presented after 6 months with the possibility of breast-conserving surgery due to clinical and radiological complete response, revealing after surgery pathological complete response. Conclusion: Eve
APA, Harvard, Vancouver, ISO, and other styles
2

Xie, J., Y. Hao, N. Li, et al. "Abstract P2-08-20: Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites." In Abstracts: Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 8-12, 2015; San Antonio, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.sabcs15-p2-08-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Nunes, Mirella Laranjeira, Maria Carolina da Trindade Henriques Assunção, Pryscila Correia de Queiroz e. Silva, et al. "METASTATIC PURE MUCINOUS BREAST CARCINOMA: A CASE REPORT." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2051.

Full text
Abstract:
Introduction: Pure mucinous breast carcinoma (PMBC) is rare, representing about 2% of breast cancers. Histologically, it is defined as having 90% or more of a mucinous component. It usually affects women between the ages of 55 and 60 years. Only 1% occurs in women below 35 years. It usually has positive hormone receptors (HRs); however, the positivity of HER-2 is rare. The management is not well established, being extrapolated from data on invasive ductal carcinoma. It usually presents a favorable prognosis, with rare lymph node (LN) involvement and metastasis rate of less than 15%. HR status
APA, Harvard, Vancouver, ISO, and other styles
4

Dooper, Marten. "OS benefit of sacituzumab govitecan in pre-treated HR-positive/HER2-negative metastatic breast cancer." In ESMO Congress 2022, edited by Stefan Rauh. Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/f0a84142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Zheng, Kelly F., Kenichi Shimada, Madeline G. Townsend, et al. "896 Characterizing macrophage heterogeneity in HR+/HER2- metastatic breast cancer reveals novel mechanisms of resistance." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0896.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hoskins, Kent F., Paul Richards, and Kari Wisinski. "Abstract 1615: First-line CDK4/6 inhibitor treatment for HR+, HER2-negative metastatic breast cancer (MBC)." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1615.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Goyal, RK, GC Carter, SN Nagar, et al. "Abstract P5-08-19: Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-p5-08-19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Rugo, H., S. Tolaney, M. Dickler, et al. "Abstract OT2-01-07: A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)." In Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.sabcs16-ot2-01-07.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

den Brok, Wendie-Lou D., Caroline Speers, Gondara Lovedeep, Emily Baxter, Scott Tyldesley, and Lohrisch Caroline. "Abstract P6-08-40: Survival of metastatic hormone receptor (HR) positive/HER2 negative; HER2+; and triple negative (TN) breast cancer based on initial presentation." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-08-40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wander, SA, LM Spring, CR Stein, et al. "Abstract P6-18-39: Abemaciclib after prior palbociclib exposure in patients with metastatic hormone-receptor positive (HR+)/HER2- breast cancer." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-18-39.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "HR+/HER2− metastatic breast cancer"

1

Hu, Wenyu, and Nanlin Li. Pyrotinib for HER2-positive metastatic breast cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.3.0076.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lyerly, H. K. Rapid Translation of a Novel and Potent Vaccine in HER2+ Metastatic Breast Cancer Patients. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada593925.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Zhang, Xiaohui, Yidong Zhou, Feng Mao, Yan Lin, Songjie Shen, and Qiang Sun. Efficacy and Safety of Anti-HER2 Agents in Combination with Chemotherapy for Metastatic HER2-positive Breast Cancer Patient: A Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2020. http://dx.doi.org/10.37766/inplasy2020.9.0086.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wang, Chuan, Ruiliang Chen, Chuangui Song, Jie Zhang, and Yushuai Yu. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2024. http://dx.doi.org/10.37766/inplasy2024.4.0092.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'HR+/HER2− metastatic breast cancer' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography